Market Overview

MetaStat Voluntarily Withdraws Listing on the OTCQB and Files Form 15 to Suspend its Reporting Obligations

Share:

MetaStat, Inc. (OTCQB:MTST) (the "Company"), a precision medicine
company developing novel anti-metastatic drugs for the treatment of
patients with aggressive cancer, today announced the Company is
voluntarily deregistering its common stock under Section 12(g) of the
Securities Exchange Act of 1934, as amended ("Exchange Act") and
suspending its reporting obligations under Section 15(d) of the Exchange
Act by filing a Form 15 with the Securities and Exchange Commission (the
"SEC") on July 16, 2018.

"After a thorough review of the benefits and risks associated with being
a public company, management and the board of directors felt
deregistering as an SEC reporting company is in the best interest of the
Company and all shareholders," stated Douglas A. Hamilton, President and
CEO of MetaStat. "It has been clear for some time the Company was not
benefiting from the public listing as the market capitalization, access
to capital and liquidity decreased despite the Company generating
positive data and executing on its product development milestones."

The Company's reporting obligations with the SEC are suspended
immediately upon filing the Form 15, including its obligations to file
annual reports on Form 10-K, quarterly reports on Form 10-Q, and current
reports on Form 8-K. The Company expects termination of its duty to file
all other reports with the SEC will become effective in 90 days.

The Company's common stock is currently quoted on the OTCQB, operated by
OTC Markets Group. The Company expects its common stock will continue to
be quoted on the OTCQB until its periodic reporting obligations under
the Exchange Act are suspended, at which time the Company anticipates
its common stock will trade on OTC Pink Market, so long as market makers
demonstrate an interest in trading in the Company's common stock.
However, there is no assurance trading in the Company's common stock
will continue on the OTC Pink Market or on any other securities exchange
or quotation medium.

About MetaStat, Inc.

MetaStat is a precision medicine company dedicated to improving the
survival of patients with aggressive cancer. Our goal is to transform
aggressive cancer into a manageable disease. MetaStat's therapeutic
approach targets the MENA pathway, a critical metastatic pathway
responsible for driving tumor resistance and the spread of aggressive
cancer. MetaStat is developing novel inhibitors targeting the MAPKAPK2
pathway based on the discovery of its role in the activation of the MENA
pathway. MetaStat is leveraging a proven and highly successful strategy
in oncology through the development of small molecule inhibitors.

Forward-Looking Statements

This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Exchange Act, and such forward-looking statements are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such statements
are subject to a multitude of risks and uncertainties that could cause
future circumstances, events or results to differ materially from those
projected in the forward-looking statements as a result of various
factors and other risks, including those set forth in the company's Form
10-K and its other filings filed with the SEC. You should consider these
factors in evaluating the forward-looking statements included herein,
and not place undue reliance on such statements. The forward-looking
statements in this release are made as of the date hereof and the
company undertakes no obligation to update such statements.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com